ASX ANNOUNCEMENT **16 October 2026**

Robert Canby, MD appointed as Chief Medical Officer

Key Highlights

- Robert Canby, MD appointed Chief Medical OfficerHe is a board-certified cardiac electrophysiologist who brings extensive experience across clinical practice, physician education, cardiovascular research, and medical device innovation
- Dr. Canby practises at the Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, Texas, and serves as President of the Texas Cardiac Arrhythmia Research Foundation
- He will continue in his clinical role at St. David's and will be working on EBR's behalf as his other duties permit
- This appointment strengthens EBR's clinical leadership as the Company advances U.S. commercial adoption and continued clinical development of the WiSE® System
- He succeeds Dr. Spencer Kubo, who has served as EBR's Chief Medical Officer since 2019

Santa Clara, California; 16 October 2026: EBR Systems, Inc. (ASX: "**EBR**", "**EBR Systems**", or the "**Company**"), developer of the world's only wireless cardiac pacing device for heart failure, announces the appointment of Robert C. Canby, M.D., as Chief Medical Officer.

Dr. Canby is a board-certified cardiac electrophysiologist with extensive experience spanning clinical practice, physician education, cardiovascular research, and medical device innovation.

He currently practices at the Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, Texas, and serves as President of the Texas Cardiac Arrhythmia Research Foundation. Dr. Canby will continue in his clinical role at St. David's and will be working on EBR's behalf as his other duties permit.

Dr. Canby, EBR Systems' Chief Medical Officer, said:

"I am excited to take on the role of EBR Systems' CMO. I have always been interested in the intersection of technology and better clinical outcomes for our patients. I have seen firsthand the benefit that EBR's technology has brought to my patients, and I hope that in this new role I can help impact even more patients. This particular technology is so important as it provides physicians with an important tool to treat patients that might otherwise not receive optimal therapy."

As Chief Medical Officer, Dr. Canby will lead EBR's medical and clinical strategy, including evidence development, physician education and engagement, and collaboration with the Company's research and development and commercial teams. He will also help ensure that patient needs continue to guide the development and adoption of the WiSE System.

For personal use only

John McCutcheon, EBR Systems' President & Chief Executive Officer, said:

"Dr. Canby is a highly respected cardiac electrophysiologist and brings an exceptional combination of clinical expertise, medical device experience and a deep understanding of cardiac electrophysiology.

His perspective as a practising physician will be invaluable as we scale adoption of the WiSE System and continue our clinical development programs.

"We welcome Bob to EBR's leadership team and look forward to his contribution as we expand access to WiSE for patients who are not well served by conventional CRT."

He succeeds Dr. Spencer Kubo, who has served as EBR's Chief Medical Officer since 2019 and is now retiring from industry. Dr. Kubo was instrumental in helping to manage SOLVE-CRT pivotal study for WiSE and in working with the FDA to gain WiSE approval. EBR wishes to express much gratitude to Dr. Kubo for his significant contributions to EBR.

Dr Canby will be participating in EBR's upcoming investor roadshow in Australia between 27 October and 29 October. Investors can register for the events being held in Brisbane, Melbourne and Sydney using the following link: https://www.surveymonkey.com/r/5XRYF9D

For more information about EBR, please visit https://www.ebrsystemsinc.com/.

ENDS

This announcement has been authorised for release by the EBR Systems Routine Disclosure Committee, a Committee of the Board of Directors.

For more information, please contact:

Company
Andrew Shute
Chief Corporate Development Officer
P: +44 7730 691421
E: investors@ebrwise.com

Investor Relations
Gabriella Hold
The Capital Network
P: +61 2 7257 7338
E: gaby@thecapitalnetwork.com.au

Julia Maguire
The Capital Network
P: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About EBR Systems

Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems' WiSE Technology

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the

For personal use only

heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device in most markets and is currently only available for sale in the US.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products and achieve broad market adoption including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. These forward-looking statements are based on EBR Systems' current expectations and inherently involve significant risks and uncertainties. EBR Systems' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of certain risks and uncertainties including those risks described in more detail in its most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents on file with the SEC from time to time and available on the SEC's website at www.sec.gov.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's ASX-traded (ASX: EBR) CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

For personal use only